Advertisement
Screener

NASDAQ:DRMA | Increase (Decrease) in Accrued Liabilities | Dermata Therapeutics, Inc.

0.0 / 5 stars · 1/120 Roast Me

Dermata Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-11

  • Dermata Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$20.63K.
  • Dermata Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$445.64K, a 410.14% decline year-over-year.
  • Dermata Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $521.75K, a 288.15% increase year-over-year.
  • Dermata Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $45.30K, a 90.46% decline year-over-year.
  • Dermata Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $14.85K, a 96.35% decline from fiscal 2024.
  • Dermata Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $407.19K.
Period endIncrease (Decrease) in Accrued Liabilities 3 monthIncrease (Decrease) in Accrued Liabilities 6 monthIncrease (Decrease) in Accrued Liabilities 9 monthIncrease (Decrease) in Accrued Liabilities 12 month
2026-06-30-$20.63K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11
-$466.27K
10-Q · filed 2026-08-11
$55.48K
derived: sum of 3 quarters · filed 2026-08-11
$100.78K
derived: sum of 4 quarters · filed 2026-08-11
2026-03-31-$445.64K
10-Q · filed 2026-05-13
$76.11K
derived: sum of 2 quarters · filed 2026-05-13
$121.42K
derived: sum of 3 quarters · filed 2026-05-13
-$574.48K
derived: sum of 4 quarters · filed 2026-08-11
2025-12-31$521.75K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26
$567.06K
derived: sum of 2 quarters · filed 2026-03-26
-$128.84K
derived: sum of 3 quarters · filed 2026-08-11
$14.85K
10-K · filed 2026-03-26
2025-09-30$45.30K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
-$650.59K
derived: sum of 2 quarters · filed 2026-08-11
-$506.90K
10-Q · filed 2025-11-14
-$372.48K
derived: sum of 4 quarters · filed 2026-08-11
2025-06-30-$695.89K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11
-$552.21K
10-Q · filed 2026-08-11
-$417.78K
derived: sum of 3 quarters · filed 2026-08-11
$56.93K
derived: sum of 4 quarters · filed 2026-08-11
2025-03-31$143.69K
10-Q · filed 2026-05-13
$278.11K
derived: sum of 2 quarters · filed 2026-05-13
$752.82K
derived: sum of 3 quarters · filed 2026-05-13
$759.25K
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$134.42K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26
$609.13K
derived: sum of 2 quarters · filed 2026-03-26
$615.56K
derived: sum of 3 quarters · filed 2026-03-26
$407.19K
10-K · filed 2026-03-26
2024-09-30$474.71K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
$481.14K
derived: sum of 2 quarters · filed 2025-11-14
$272.77K
10-Q · filed 2025-11-14
2024-06-30$6.43K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
-$201.94K
10-Q · filed 2025-08-13
2024-03-31-$208.37K
10-Q · filed 2025-05-14